Table 1.

Pooled effect sizes (95% confidence interval in parenthesis) of short-term primary outcome variables in comparison of SGAs and FGAs.

SGA	FGA	# studies	n	All-cause Discontinuation Rate (RR)	Symptom Reduction (Hedges’ g)	Response Rate (RR)
Olanzapine	Haloperidol	5	689	0.53 (0.37~0.77)**	0.26 (0.05~0.47)*	1.29 (1.05~1.58)*b
Olanzapine	Molindone	1	75	1.37 (0.82~2.29)	−0.02 (−0.47~0.43)	0.68 (0.39~1.19)
Risperidone	Haloperidol	5	1146	0.79 (0.63~0.97)*a	−0.04 (−0.19~0.11)	1.04 (0.90~1.20)c
Risperidone	Molindone	1	81	0.85 (0.46~1.54)	−0.15 (−0.58~0.28)	0.92 (0.58~1.45)
Risperidone	Zuclopenthixol	1	25	NR	0.50 (−0.29~1.28)	1.34 (0.30~5.96)
Clozapine	Chlorpromazine	1	160	0.91 (0.37~2.25)	0.15 (−0.16~0.46)	1.03 (0.88~1.20)
Amisulpride	Haloperidol	1	207	0.63 (0.47~0.85)**	0.40 (0.13~0.68)**	1.56 (1.13~2.15)**
Quetiapine	Haloperidol	1	207	0.81 (0.63~1.05)	0.26 (−0.02~0.53)	1.30 (0.92~1.84)
Ziprasidone	Haloperidol	1	185	0.89 (0.68~1.15)	0.22 (−0.07~0.51)	1.11 (0.76~1.64)
Pooled SGAs	Pooled FGAs	12	1952	0.74 (0.62~0.87)**	0.11 (−0.02~0.24)	1.13 (0.99~1.27)

Note: # studies and n are the largest possible for each comparison pair, but # of studies and n for each outcome may vary.

^*p < .05;

^**p < .01.

^aN=4, n=1146;

^bN=4, n=652;

^cN=4, n=1089.